High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome

Authors

  • Lihua Xu Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, Jiangsu, China; Department of Pediatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
  • Yang Guo Department of Pediatrics, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, China
  • Wenying Yan Center for Systems Biology, Soochow University, Suzhou, 215006, Jiangsu, China
  • Jiannong Cen The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, China
  • Yuna Niu School of Laboratory Medicine, Xinxiang Medical University, Xinxiang, 453003, Henan, China
  • Qing Yan Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, Jiangsu, China
  • Hailong He Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, Jiangsu, China
  • Chien-Shing Chen Department of Internal Medicine, Division of Hematology and Medical Oncology & Biospecimen Laboratory, Loma Linda University, Loma Linda, CA 92350, USA
  • Shaoyan Hu Department of Hematology and Oncology, Children's Hospital of Soochow University, Suzhou 215003, Jiangsu, China

DOI:

https://doi.org/10.17179/excli2016-707

Keywords:

miR-196b, AML, pediatric/child, biomarker

Abstract

Differential expression of microRNAs (miRNAs) has been implicated in leukemogenesis. We investigate the expression pattern of miR-196b. Using quantitative real-time PCR (qRT-PCR), we detected the expression of miR-196b and its correlated genes (SMC1A/MLH1) in initial pediatric AML. A significant association was observed between overexpression of miR-196b and inferior overall survival of pediatric AML (Log Rank P<0.0001). AML M4/5 subtype, high white blood cell (WBC) count at presentation, MLL rearrangement, or FLT3-ITD mutation at diagnosis and non-remission group after the first induction chemotherapy possessed higher miR-196b expression. Furthermore, a positive relationship was found between the expression of miR-196b and SMC1A/MLH1 (Spearman's r=0.37 and 0.44, P=0.001 and <0.0001, respectively). Taken together, these findings suggest that differentially high expression of miR-196b in diagnostic marrow samples of pediatric AML is associated with unfavorable outcome, and miR-196b potentially can be a novel biomarker for the diagnosis, prognosis and treatment in pediatric AML.

Downloads

Published

2017-03-07

How to Cite

Xu, L., Guo, Y., Yan, W., Cen, J., Niu, Y., Yan, Q., … Hu, S. (2017). High level of miR-196b at newly diagnosed pediatric acute myeloid leukemia predicts a poor outcome. EXCLI Journal, 16, 197–209. https://doi.org/10.17179/excli2016-707

Issue

Vol. 16 (2017)

Section

Original articles

License

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).